Raymond James analyst Ryan Deschner initiated coverage of ARS Pharmaceuticals with an Outperform rating and $18 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals Updates Corporate Presentation Online
- ARS Pharmaceuticals: Corporate Update and EURneffy’s Positive Opinion
- ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals: EURneffy recommended for approval by CHMP